After decades, a new treatment

Posted 8 May 2024 AM

GSK's PD-1 inhibitor Jemperli has leapfrogged MSD's Keytruda in treating endometrial cancer, snagging funding for a first-line listing.

That makes it the first new first-line treatment for endometrial cancer in decades, approved by the TGA just this January through the regulatory collaboration Project Orbis. Last year MSD's Keytruda became the first PD-1 inhibitor combination treatment to be listed on the PBS for endometrial cancer, as an option following treatment with chemotherapy regardless of biomarker status.

To see the whole article, please login